Algernon Pharmaceuticals Announces Closing of the Acquisitio

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Canada , Vancouver , British Columbia , United Kingdom , Canadian , British , Dietricha Stephan , Christopherj Moreau , Algernon Ifenprodil , Maxim Group , Canadian Securities Exchange , Neither The Canadian Securities Exchange , Algernon Pharmaceuticals Announces Closing Of The Acquisition , Merck Co , Algernon Pharmaceuticals , Drug Administration , No Securities Exchange , Bellus Health , Afferent Pharmaceuticals , Company Or Algernon , Algernon Pharmaceuticals Inc , Seyltx Inc , Chronic Cough Research Program , Market Research , Pharmaceuticals Announces Closing , Chief Executive , Investigational New Drug , Data Bridge Market Research , Algernon Neuroscience , Market Regulator ,